International Review of Psychiatry
June 5, 2024
Katherine Cheung, Caleigh Propes, Edward Jacobs et al.
11 citations
Psychedelic integration groups, offered in person or online, may attract individuals who feel disconnected or lonely after a psychedelic experience. These groups can provide community and shared coping strategies, but also carry risks. This essay explores both benefits and risks, offering preliminary guidelines for physicians, researchers, and individuals to assess and evaluate such groups.
JAMA Health Forum
November 7, 2025
Caleigh Propes, Katherine Cheung, Matthew D. Eisenberg et al.
4 citations
This viewpoint outlines strategies for addressing policy gaps that would arise if the US Food and Drug Administration approves psychedelics for treating mental health and substance use conditions. It discusses regulatory, clinical, and public health considerations necessary to integrate these therapies into practice.
AJOB empirical bioethics
July 16, 2025
Katherine Cheung, Caleigh Propes, Marianna Graziosi et al.
4 citations
Informed consent documents from U.S. psilocybin clinical trials often emphasize mental health and physical risks but rarely include psychedelic-specific elements like ineffability or therapeutic touch, despite calls from bioethicists for tailored consent forms. A content analysis of 28 documents from 13 sites found good coder reliability. The results suggest that while general risks are well covered, the unique features of psychedelic experiences are not consistently addressed in consent materials. The authors recommend ongoing debate about which elements are most important for potential participants to consider when deciding whether to join a study.
American Journal of Bioethics
July 30, 2025
Caleigh Propes, Katherine Cheung
1 citation
Informed consent is intended to give potential study participants clear information about risks and benefits, but participants often misunderstand key aspects of what they are told. The paper examines the persistent problem of participant misconceptions in medical and psychological research, discussing how these misunderstandings undermine the ethical goals of informed consent and suggesting possible reasons and remedies.
International Journal of Drug Policy
June 13, 2026
Katherine Cheung, Caleigh Propes, David B. Yaden
Oregon's psilocybin services program, established under the Psilocybin Services Act, allows adults over 21 to access psilocybin at licensed service centers with facilitator supervision but without a medical referral or clinical oversight. Analysis of the first full year of Oregon Health Authority data shows reported adverse reactions were relatively uncommon in 2025, though the reporting framework sets a high threshold for reportable events. Access remains limited, with most clients being high-income and from outside Oregon. The program has expanded supervised psilocybin use beyond strictly medical uses, with some clients using services for general wellness and others for depression or anxiety. The authors argue that broad eligibility criteria and supervision requirements may raise safety concerns, especially for clients with clinical symptoms.